Bioinformatics and epigenetics - computer-aided cancer diagnosis
Methylated bases of DNA - highlighted with bright dots in this image - deactivate a gene. The methylation pattern reveals if chemotherapy is effective against a tumour, here visible as a bright spot in the brain section. Credit: MPI for Informatics
The relatively young research field of epigenetics is the talk of the town. Many scientists expect the research on biochemical modifications beyond the actual DNA strand to lead to huge progress in the understanding of the regulation of gene activity in the years to come. Just how promising the results of epigenetic research are in terms of concrete medical applications is demonstrated by the work of Thomas Lengauer and Christoph Bock from the Max Planck Institute for Informatics in Saarbrücken. With the help of computers, they trawl through the genomes of cancer patients in search for suspect structures, and develop fast and simple new tools for improving cancer diagnosis in hospitals.
Although the human body consists of a scarcely conceivable 10 to 100 billion cells, it only takes a few diseased cells to cause cancer. Minor damage in the DNA as a result of exposure to UV light or tobacco smoke can switch off a cells natural growth limits: the cell then starts to divide uncontrollably and, in the worst-case scenario, overgrow healthy tissue in the form of tumours, which eventually destroy vital organs.
It was long believed that only changes in the DNA itself play a crucial role in the emergence of cancer. However, it is now clear that the biochemical coat of the DNA strand also has an important role to play, as a cells genetic material is modified by a large number of chemical attachments. DNA methylation, in particular, plays a central role in gene regulation: small hydrocarbon attachments thus decide whether a gene is active or silenced, namely whether it can be read off or not.
Defects in DNA methylation result in altered gene activity in the cell which can contribute to tumour formation. In addition, the methylation patterns of tumor cells differ clearly from those of healthy tissue cells. This is the precise point where our research begins, says Thomas Lengauer from the Max Planck Institute for Informatics in Saarbrücken, who, together with Christoph Bock, leads the Computational Epigenetics Research Group in Professor Lengauers Department of Computational Biology and Applied Algorithmics.
The scientists rummage through vast collections of genetic data for suspicious methylation patterns using software programs they develop themselves. Many of these patterns only arise in very specific types of cancer, so we can use them in clinical diagnosis as biomarkers, that is to say as indicators for the corresponding form of the disease, says Thomas Lengauer. The scientists rely on close cooperation with hospitals and biotechnology laboratories for their work. The tissue samples from cancer patients are processed in the laboratory and the genetic material they contain is cut into numerous small snippets. The solution is then processed using microarrays (DNA chips) or using new-generation sequencing processes. Eventually you get a kind of map of the epigenome, which comprises all of the biochemical markings layered on top the actual DNA sequence, explains Thomas Lengauer.
The subsequent mathematical analyses by the Saarbrücken-based researchers are carried out exclusively in the computer. Ingenious algorithms and statistical processes screen the sea of epigenome data for patterns that only arise in certain forms of cancer and are absent in healthy patients a task that requires a lot of careful programming. Because, unlike the genome, which is almost identical in all of the bodys cells, the DNAs chemical coat is a real chameleon. There are around 200 different types of tissue in the human body, each with different epigenomes. These also change with advancing age and in the presence of disease, says Thomas Lengauer. We have to take all of these variations into account in our programs to ensure that only differences relevant to cancer are considered important.
And all of this effort is proving worthwhile. Working in collaboration with the Universitätsklinikum Bonn, the scientists in Saarbrücken developed an epigenetic biomarker for malignant glioblastoma, the most common form of malignant brain tumor. Chemotherapy is only effective in around one quarter of affected patients, explains Christoph Bock, who also leads a research group at the Research Center for Molecular Medicine in Vienna. In these patients, a particular gene called MGMT is methylated, that is silenced. In its active state, this gene controls a repair mechanism in the cancer cells. In patients with active MGMT, the DNA damage arising during chemotherapy, which causes diseased cells to die, would be reversed and the treatment fails. With the help of the new biomarker, the hospital can now identify in advance of treatment those patients for whom debilitating chemotherapy is actually worthwhile. The researchers subsequently systematised the time-consuming manual procedure for the identification of this biomarker and developed a corresponding software program. Using this software, other innovative biomarkers for cancer can now be identified considerably faster.
The researchers latest success has also opened up completely new paths in clinical cancer diagnosis. In a major international project headed by Manel Esteller from the Bellvitge Biomedical Research Institute in Barcelona, Spain, over 1,600 human tissue samples were analysed. The methylation pattern was sampled at around 1,500 characteristic places in each analysed genome and the resulting data analysed by computer at the MPI in Saarbrücken. The results of the analysis are very promising. Even more significant, however, is the fact that, based on the methylation patterns, the researchers were able to classify tumours that belong to the cancers of unknown primary origin group, known as CUPs.
Imagine that a patient comes to the doctor complaining about pains in his liver, says Christoph Bock. The doctor then establishes that numerous metastases originating from an unknown primary tumor have already formed in the liver. When such malignant cancer cells of unknown origin are found in the body, the frantic search for the primary tumour begins. In around 25 percent of cases, this search is unsuccessful. Because cancer cells frequently degenerate outside their original tissue, without knowing the origin of the primary tumour, it is almost impossible to establish what kind of cancer is involved and this, in turn, significantly reduces the patients chances of a successful cure. Through epigenome analysis we were able to assign 70 percent of the CUPs in our samples definitively to one type of cancer, says Christoph Bock. Therefore, analytical tools like those we have developed for glioblastoma can improve the prognosis for these patients because the hospital then can select the treatment best suited to their condition.
In the meantime, the potential offered by epigenome mapping has also been recognised at an international level. Various major projects are being coordinated under the aegis of the International Epigenome Consortium (IHEC). The general aim is to completely map the epigenomes of at least 1,000 biologically and medically significant cell types and cell states. The individual projects within the IHEC focus on different issues. Whereas, for example, the US institutes are aiming to create reference profiles for as many healthy human cell types as possible, the EU-funded BLUEPRINT project is focusing on the cells of the blood and immune system. The approach adopted by BLUEPRINT is extremely application-oriented as many clinical diagnoses are based on the analysis of blood samples, says Christoph Bock. In addition to around 60 healthy cell types in the blood, it is also intended to map over 60 forms of leukaemia. The MPI in Saarbrücken is not the only Max Planck Institute involved in IHEC: the MPI of Immunobiology and Epigenetics in Freiburg and the MPI for Molecular Genetics in Berlin are also participating in this project.
Thanks to bioinformatics, our knowledge in the field of epigenetics will proliferate in the decade to come, says Thomas Lengauer. The professor from Saarbrücken continues: In future, epigenetics will form the backbone of the explanation as to how cells control themselves a central question in biology. With the help of bioinformatics-related methods it will be possible to discover many processes in the cell nucleus that are still completely unknown, in particular the regulation of gene activity.
Data management is the first task in the long to-do list. The wave of data that is now approaching is nothing short of revolutionary, says Thomas Lengauer. Here in Saarbrücken, the servers are bursting at the seams, so much so that we are currently considering moving our data, in part at least, to the cloud. Obviously, the epigenome maps must be stored in a network, be easily accessible and be made usable with the help of suitable tools and search engines. The alternative now being given serious consideration would mean that laboratories and clinics would have to re-sequence stored samples each time they need them, simply because there is no space to store the data, says Lengauer. A highly remote solution for computer scientists at least.
Although Thomas Lengauer regards epigenome analysis as playing a crucial role in the attainment of rapid progress in cancer diagnosis in the near future, he plays down expectations with regard to the development of new drugs. Many scientists point to the potential of future drugs that can repair defects in the epigenome of diseased cells. I tend to be more cautious in this regard. Such targeted interventions involve significant risks, not least because little or nothing is currently known about the highly-complex gene regulation mechanisms being manipulated here.
Provided by Max-Planck-Gesellschaft
- Potential for earlier diagnosis of ovarian cancer Jan 25, 2012 | not rated yet | 0
- DNA 'off switch' may reverse premature aging Jun 15, 2011 | not rated yet | 0
- There is no such thing as identical where twins are concerned Oct 14, 2011 | not rated yet | 0
- Match your treatment to your cancer Jun 30, 2011 | not rated yet | 0
- Discoveries in mitochondria open new field of cancer research Jun 20, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013 As an experiment, for the past few months I've been consuming at least one portion of Jell-O or unflavored Knox gelatin per day. I'm 64, in very...
Alcohol and acetaminophen
May 13, 2013 Edit: sorry for the typo in the title , can't edit I looked around on google quite a bit and it's very hard to find precise information on the...
Marie Curie's leukemia
May 13, 2013 Does anyone know what might be the cause of Marie Curie's cancer
- More from Physics Forums - Medical Sciences
More news stories
In a new study described in the journal Oncogene, researchers reveal how a key player in cell growth, immunity and the inflammatory response can be transformed into a primary contributor to tumor growth.
Cancer 1 hour ago | not rated yet | 0 |
A new study conducted using extensive medical records of over one million Israeli adolescents before military service shows clearly how exposure to the Israeli sun of young, light-skinned children increases substantially ...
Cancer 3 hours ago | not rated yet | 0
A new measure of the heterogeneity – the variety of genetic mutations – of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue ...
Cancer 7 hours ago | not rated yet | 0
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis—two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic ...
Cancer 8 hours ago | not rated yet | 0
The use of a smartphone application significantly improves patients' preparation for a colonoscopy, according to new research presented today at Digestive Disease Week (DDW). The preparation process, which begins days in ...
Cancer May 19, 2013 | not rated yet | 0
There is a link between use of anabolic-androgenic steroids and reduced mental health later in life. This is the main conclusion of a new study on elite male strength athletes that researchers from the University of Gothenburg ...
51 minutes ago | not rated yet | 0
Over the past few decades, neuroscientists have made much progress in mapping the brain by deciphering the functions of individual neurons that perform very specific tasks, such as recognizing the location ...
1 hour ago | not rated yet | 0 |
High-intensity, short duration warm up activities at half time intervals boost athletic performance, a study of soccer players has found.
1 hour ago | not rated yet | 0
(Medical Xpress)—Bullying because of perceived sexual orientation is prevalent among school-aged youths, according to a study led by Donald Patrick, professor of health services at the UW School of Public ...
1 hour ago | not rated yet | 0
Melbourne researchers have identified an immune protein that has the potential to stop or reverse the development of type 1 diabetes in its early stages, before insulin-producing cells have been destroyed.
4 hours ago | 5 / 5 (1) | 0 |
More than a decade ago, British parents refused to give measles shots to at least a million children because of a vaccine scare that raised the specter of autism. Now, health officials are scrambling to catch ...
4 hours ago | not rated yet | 0